These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 21878891)

  • 1. Challenges translating breast cancer gene signatures into the clinic.
    Weigelt B; Pusztai L; Ashworth A; Reis-Filho JS
    Nat Rev Clin Oncol; 2011 Aug; 9(1):58-64. PubMed ID: 21878891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
    Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
    BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.
    Yau C; Esserman L; Moore DH; Waldman F; Sninsky J; Benz CC
    Breast Cancer Res; 2010; 12(5):R85. PubMed ID: 20946665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.
    Colombo PE; Milanezi F; Weigelt B; Reis-Filho JS
    Breast Cancer Res; 2011 Jun; 13(3):212. PubMed ID: 21787441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multigene prognostic tests in breast cancer: past, present, future.
    Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
    Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
    Karn T; Pusztai L; Holtrich U; Iwamoto T; Shiang CY; Schmidt M; Müller V; Solbach C; Gaetje R; Hanker L; Ahr A; Liedtke C; Ruckhäberle E; Kaufmann M; Rody A
    PLoS One; 2011; 6(12):e28403. PubMed ID: 22220191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer.
    Kwon MJ
    Arch Pharm Res; 2019 Nov; 42(11):947-961. PubMed ID: 31707598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.
    Prat A; Parker JS; Fan C; Cheang MCU; Miller LD; Bergh J; Chia SKL; Bernard PS; Nielsen TO; Ellis MJ; Carey LA; Perou CM
    Ann Oncol; 2012 Nov; 23(11):2866-2873. PubMed ID: 22532584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
    Acharya CR; Hsu DS; Anders CK; Anguiano A; Salter KH; Walters KS; Redman RC; Tuchman SA; Moylan CA; Mukherjee S; Barry WT; Dressman HK; Ginsburg GS; Marcom KP; Garman KS; Lyman GH; Nevins JR; Potti A
    JAMA; 2008 Apr; 299(13):1574-87. PubMed ID: 18387932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gene signatures for breast cancer, clinical utility and therapeutic applications].
    Vargas-Aguilar VM; Arroyo-Alvarez K
    Rev Med Inst Mex Seguro Soc; 2018; 56(2):180-185. PubMed ID: 29906029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
    Kuo WH; Chang YY; Lai LC; Tsai MH; Hsiao CK; Chang KJ; Chuang EY
    PLoS One; 2012; 7(9):e45831. PubMed ID: 23049873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy.
    Hallett RM; Pond G; Hassell JA
    BMC Med Genomics; 2012 May; 5():16. PubMed ID: 22578285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.
    Yau C; Sninsky J; Kwok S; Wang A; Degnim A; Ingle JN; Gillett C; Tutt A; Waldman F; Moore D; Esserman L; Benz CC
    Breast Cancer Res; 2013; 15(5):R103. PubMed ID: 24172169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic classification of breast cancer and gene expression profiling].
    Bertucci F; Finetti P; Cervera N; Birnbaum D
    Med Sci (Paris); 2008; 24(6-7):599-606. PubMed ID: 18601877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.
    Fan C; Prat A; Parker JS; Liu Y; Carey LA; Troester MA; Perou CM
    BMC Med Genomics; 2011 Jan; 4():3. PubMed ID: 21214954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of early breast cancer patient survival using ensembles of hypoxia signatures.
    Gong IY; Fox NS; Huang V; Boutros PC
    PLoS One; 2018; 13(9):e0204123. PubMed ID: 30216362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients.
    Tobin NP; Lindström LS; Carlson JW; Bjöhle J; Bergh J; Wennmalm K
    Mol Oncol; 2014 May; 8(3):741-52. PubMed ID: 24630985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
    Correa Geyer F; Reis-Filho JS
    Int J Surg Pathol; 2009 Aug; 17(4):285-302. PubMed ID: 19103611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.